- Halozyme Therapeutics reported third quarter 2026 revenue of US$492.97 million and net income of US$247.05 million, with both revenue and earnings per share above analyst estimates and accompanied by higher full year guidance.
- The company leaned further into its royalty and partnership model, as expanded ENHANZE collaborations and new Phase 1 programs added more potential long duration revenue streams.
- We will look at how Halozyme Therapeutics' royalty heavy investment narrative is affected by the latest earnings beat and expanded ENHANZE collaborations.
Compare Halozyme Therapeutics' royalty-heavy model with other potential compounders by scanning a curated set of 42 high quality undervalued stocks that pair resilient cash flows with solid balance sheets.
Halozyme Therapeutics Investment Narrative Recap
To stay invested in Halozyme Therapeutics, you need to be comfortable with a royalty driven story that depends on partners continuing to push subcutaneous and at home biologic delivery. The latest quarter reinforced that thesis, with US$492.97 million in revenue and US$247.05 million in net income. The company also raised full year guidance, which suggests management still sees momentum in the underlying franchise.
The near term swing factor is execution on ENHANZE launches and new Phase 1 programs translating into durable royalty streams rather than one off upside. The biggest risk still centers on pricing and reimbursement pressure, along with competing subcutaneous platforms that could dilute Halozyme Therapeutics' bargaining power on future deals.
The most relevant development tied to this earnings report is the expansion of Halozyme Therapeutics' ENHANZE collaboration agreements, along with three programs moving into Phase 1. That directly relates to the core thesis that a broader partner and product base can extend royalty duration and reduce dependence on any single drug or company.
For catalysts, those added ENHANZE targets and early stage trials give investors more potential opportunities that could feed into the royalty line if they succeed. In addition, the Dutch patent court injunction against Merck's Keytruda Qlex in parts of Europe illustrates active defense of the franchise. Both factors run counter to some competitive and policy related risks but still require consistent operational follow through to be meaningful for the long term story.
Halozyme Therapeutics' narrative projects US$2.3b revenue and US$1.2b earnings by 2029. This implies 10.6% yearly revenue growth and an earnings increase of about US$786.4m from US$413.6m today.
Uncover why Halozyme Therapeutics' fair value indicates a 12% potential downside to its current price, which leaves little room for error.
Exploring Other Perspectives
One alternate view focuses on competition risk. The most bearish Halozyme Therapeutics analysts argued that rivals such as ALT B4 could limit royalty potential and supported a US$78 price target, even while estimating about US$2.3b of revenue and US$1.3b of earnings for 2029. Those estimates were set before this earnings surprise, so you may want to monitor how opinions evolve and consider how different scenarios compare.
Explore 4 other Halozyme Therapeutics fair value estimates, including one that suggests as much as 12% downside from the current price.
Decide For Yourself
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Halozyme Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Halozyme Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.
Looking for more Halozyme Therapeutics style ideas?
If the Halozyme Therapeutics royalty story appeals to you but you want a broader watchlist, the Simply Wall St Screener can help you quickly sort through companies with different strengths and risk profiles.
- For investors who prize financial resilience first, you could start with businesses screened for sturdy balance sheets and solid fundamentals through the list of solid balance sheet and fundamentals (24 results).
- If your priority is finding potentially underpriced opportunities with quality characteristics, you could filter for stocks that combine fundamental strength with appealing valuations using the 42 high quality undervalued stocks.
- For a more cautious approach that tilts toward stability, you might look at companies with relatively lower overall risk scores by running the 32 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com